Rituximab in dermatology;Rituximab en dermatología

Actas Dermo-Sifiliograficas

Volumn 104, Issue 5, 2013, Pages 380-392

  Espana A ^a   Ornilla, E ^a   Panizo, C ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Anti CD20 antibodies; Autoimmunity; B cell

Indexed keywords

CD20 ANTIBODY; RITUXIMAB;

ARTICLE; B LYMPHOCYTE; CLINICAL PRACTICE; DERMATOLOGIST; DRUG INDICATION; PRACTICE GUIDELINE;

EID: 84880606360     PISSN: 00017310     EISSN: 15782190     Source Type: Journal    
DOI: 10.1016/j.ad.2012.02.008     Document Type: Short Survey

References (73)

1. Cunliffe WJ. Evolution of a strategy for the treatment of acne. J Am Acad Dermatol. 1987;16:591-9.
2. Pettit JH. Oral retinoid for psoriasis. A report of a double blind study. Acta Derm Venereol Suppl (Stockh). 1979;59:133-6.
3. Page EH, Wexler DM, Guenther LC. Cyclosporin A. J Am Acad Dermatol. 1986;14:785-91.
4. Léauté-Labrèze C, Dumas de la Roque E, Hubiche T, Boralevi F, Thambo JB, Taïeb A. Propranolol for severe hemangiomas of infancy. N Engl J Med. 2008;358:2649-51.
5. Press OW, Appelbaum F, Ledbetter JA, Martin PJ, Zarling J, Kidd P, et al. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell ymphomas. Blood. 1987;69:584-91.
6. Martin F, Chan AC. Pathogenic roles of B cells in human autoim-munity: insights fron the clinic. Immunity. 2004;20:517-27.
7. Nagel A, Hertl M, Eming R. B-cell directed therapy for immflamatory skin diseases. J Invest Dermatol. 2009;129:289-301.
8. Emer JJ, Wolinsky C. Rituximab. A review of dermatological applications. J Clin Aesthetic Dermatol. 2009;2:29-37.
9. Hertl M, Zillikens D, Borradori L, Bruckner-Tuderman L, Buckhard H, Eming R, et al. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges. 2008;6:366-74.
10. Carr DR, Heffernan MP. Off-label uses of rituximan in dermatology. Dermatol Ther. 2007;20:277-87.
11. Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun. 2005;8:140-74.
12. Vugmeyster Y, Beyer J, Howell K, Combs D, Fielder P, Yang J, et al. Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis. J Immunother. 2005;28:212-9.
13. Hamaguchi Y, Uchida J, Cain DW, Venturi GM, Poe JC, Haas KM, et al. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunothe-rapy in mice. J Immunol. 2005;174:4389-99.
14. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, et al. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. J Immunol. 2005;174:817-26.
15. Schmidt E, Hunzelmann N, Zillikens D, Bröcker EB, Goebeler M. Rituximab in refractory autoimmune bullous doiseases. Clin Exp Dermatol. 2006;31:503-8.
16. Binstadt BA, Geha RS, Bonilla FA. IgG Fc receptor polymorphisms in human disease: implications for intravenous immunoglobulin therapy. J Allergy Clin Immunol. 2003;111: 697-703.
17. Uchida J, Hamaguchi Y, Oliver JA, Ravetch JV, Poe JC, Haas KM, et al. The innate mononuclear phagocyte network repletes B lymphocytes through Fc receptor-dependent mechanisms during anti-Cd20 antibody immunotherapy. J Exp Med. 2004;199:1659-69.
18. Nagel A, Podstawa E, Eickmann M, Müller HH, Hertl M, Eming R. Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. J Invest Dermatol. 2009;129:2202-10.
19. Tokunaga M, Fujii K, Saito K, Nakayamada S, Tsujimura S, Nawata M, et al. Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematous after successful treatment with rituximab. Rheumatology. 2005;44:176-82.
20. Tokunaga M, Saito K, Kawabata D, Imura Y, Fujii T, Nakayamada S, et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis. 2007;66:470-5.
21. Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum. 2005;52:501-13.
22. Sfikakis PP, Boletis JN, Tsokos CC. Rituximab anti-B-cell therapy in systemic lupus eruthematosus: pointing to the future. Curr Opin Rheum. 2005;17:550-7.
23. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest. 1996;97:2063-73.
24. Toubi E, Kessel A, Slobodin G, Boulman N, Paviotzky E, Zisman D, et al. Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis. Ann Rheum Dis. 2007;66:818-20.
25. Vigna-Perez M, Hernandez-Castro B, Paredes-Saharopulos O, Portales-Perez D, Baranda L, Abud-Mendoza C, et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to convencional therapy: a pilot study. Arthritis Res Ther. 2006;8:R83.
26. Sfikakis PP, Souliotis VL, Fragiadaki KG, Moutsopoulos HM, Boletis JN, Theofilopoulos AN. Increased expression of the FoxP3 functional marker of regulatory T cells following B cell deplection with rituximab in patients with lupus nephritis. Clin Immunol. 2007;123:66-73.
27. Vallerskog T, Gunnarsson I, Widhe M, Risselada A, Klareskog L, van Vollenhoven R, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol. 2007;122: 62-74.
28. Vos K, Thurlings RM, Wijbrandts CA, van Schaardenburg D, Gerlag DM, Tak PP. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum. 2007;56:772-8.
29. Eming R, Nagel A, Wolff-Franke S, Podstawa E, Debus D, Hertl M. Rituximab exerts a dual effect in pemphigus vulgaris. J Invest Dermatol. 2008;128:2850-8.
30. España A, Fernandez-Galar M, Lloret P, Sánchez-Ibarrola A, Panizo C. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immu-nophenotype correlations. JAm Acad Dermatol. 2004;50:974-6.
31. Anolik JH, Barnard J, Cappione A, Pugh-Bernard AE, Felgar RE, Looney RJ, et al. Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus. Arthritis Rheum. 2004;50:3580-90.
32. Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC. Reconstitution of peripheral bllod B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:613-20.
33. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, White CA, Liles TM, Royston I, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin lymphoma. Blood. 1997;90:2188-95.
34. Roll P, Palanichamy A, Kneitz C, Corner T, Tony HP. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. Arthritis Rheum. 2006;54:2377-86.
35. Ng KP, Cambridge G, Leandro MJ, Edwards JC, Ehrenstein M, Isenberg DA. B cell depletion therapy in systemic lupus erythe-matosus: long-term follow-up and predictors of response. Ann Rheum Dis. 2007;66:1259-62.
36. Cheng L, Genovese MC, Florentino DF. A pilot trial in the treatment of patients with dermatomyositis. Arch Dermatol. 2007;143:763-7.
37. Simon D, Solí S, Kostylina G, Yawalkar N, Simon HU. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol. 2008;121:122-8.
38. Fink-Puches R, Wolf IH, Zalaudek I, Kerl H, Cerroni L. Treatment of primary cutaneous B-cell lymphoma with rituximab. J Am Acad Dermatol. 2005;52:847-53.
39. KerlK Prins C, Saurat JH, French LE. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases. Br J Dermatol. 2006;155: 1197-200.
40. Martin SJ, Duvic M. Treatment of cutaneous lymphoid hyper-plasia with the monoclonal anti-CD20 antibody rituximab. Clin Lymphoma Myeloma Leuk. 2011;11:286-8.
41. Albert D, Dunham J, Khan S, Stansberry J, Kolasinsky S, Tsai D, et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythematosus. Ann Rheum Dis. 2008;67:1724-31.
42. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis. 2002;61:883-8.
43. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56:3896-8.
44. Schmidt E, Seitz CS, Benoit S, Bröcker EB, Goebeler M. Rituximab in autoimmune bullous diseases: mixed responses and adverses effects. Br J Dermatol. 2007;156:352-6.
45. Belgi AS, Azeez M, Hoyle C, Williams RE. Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed. Clin Exp Dermatol. 2006;31:143.
46. España A, Iranzo P, Ciudad C, Suárez R. Tratamiento con rituxi-mab del pénfigo vulgar y pénfigo foliáeo en28 pacientes: estudio nacional en tres hospitales. Póster presentado en el Congreso Nacional de la Academia Española de Dermatología, Málaga, 26-29 de mayo de 2010.
47. Hainsworth JD. Safety of rituximab in the treatment of B cell malignancies: implications for rhematoid artritis. Arthritis Red Ther. 2003;5 Suppl. 4:S12-6.
48. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Arthritis Rheum. 2006;54:1390-400.
49. Goebeler M, Herzog S, Brocker EB, Zillikens D. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol. 2003;149:899-901.
50. Schmidt E, Herzog S, Bröcker EB, Zillikens D. Rituximab induced long-standing remission in a 14-year-old boy with treatment-resistant pemphigus vulgaris. Br J Dermatol. 2005;153: 449-51.
51. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, Edwards JC. Serological changes following B cell depletion therapy for rheumatoid arthritis. Arthritis Rheum. 2003;48: 2146-54.
52. Goto S, Goto H, Tanoshima R, Kato H, Takahashi H, Sekiquchi O, et al. Serum sickness with an elevated level of human anti-chimeric antibody following treatment with rituximab in a child with chronic immune thrombocytopenic purpura. Int J Hematol. 2009;89:305-9.
53. Cheson BD. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of the B-cell malignancies. J Clin Oncol. 2010;28:3525-30.
54. Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood. 2011;117:1499-506.
55. Kong HH, Prose NS, Ware RE, Hall 3rd RP. Successful treatment of refractory childhood pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Pediatr Dermatol. 2005;22: 461-4.
56. Gellrich S, Muche JM, Wilks A, Jasch KC, Voit C, Fischer T, et al. Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas - an applicational observation. Br J Dermatol. 2005;153:167-73.
57. Suarez-Fernandez R, España A, Herrero J, Mascaro JM. Manejo práctico de las enfermedades ampollosas autoinmunes más fre-cuentes. Actas Dermosifiliogr. 2008;99:441-55.
58. Joly P, Bouquet H, Roujeau JC, Dǐincan M, Gilbert D, Jacquot S, et al. A single cycle of rituximab for the treatment of severe pemphigus. N Engl J Med. 2007;357:545-52.
59. Cianchini G, Corona R, Frezzolini A, Ruffelli M, Didona B, Puddu P. Treatment of Severe Pemphigus With Rituximab. Report of 12 Cases and a Review of the Literature. Arch Dermatol. 2007;143:1033-8.
60. Schmidt E, Benoit S, Broker EB, Zillikens D, Goebeler M. Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab. Arch Dermatol. 2006;142:147-50.
61. Lourari S, Herve C, Doffoel-Hantz V, Meyer N, Bulai-Livideanu C, Viraben R, et al. Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. J Eur Acad Dermatol Venereol. 2011;25:1238-40.
62. Kim SJ, Lee JW, Jung CW, Min CK, Cho B, Shin HJ, et al. Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase ii study. Haematologica. 2010;95:1935-42.
63. Levine TD. Rituximab in the treatment of dermatomyositis: an open-label pilot study. Arthritis Rheum. 2005;52:601-7.
64. WinkF, Houtman PM, Jansen TL. Rituximabin cryoglobulinaemic vasculitis, evidence for its effectivity: a case report and review of literature. Clin Rheumatol. 2011;30:293-300.
65. Pietrogrande M, De Vita S, Zignego AL, Pioltelli P, Sansonno D, Sollima S, et al. Recommendations for the management of mixed cryoglobulinemia syndrome in hepatitis C virus-infected patients. Autoimmun Rev. 2011;10:444-54.
66. Levi M, Hack CE, van Oers MH. Rituximab-induced elimination of acquired angioedema due to C1-inhibitor deficiency. Am J Med. 2006;119:e3-5.
67. Trappe R, Loew A, Thuss-Patience P, Dörken B, Riess H. Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab-monitoring of antiphospholipid and anti-GP antibodies: a case report. Ann Hematol. 2006;85:134-5.
68. Ramos-Casals M, Brito-Zerón P, Muñoz S, Soto MJ, BIOGEAS STUDY Group. A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore). 2008;87:345-64.
69. Terrier B, Amoura Z, Ravaud P, Hachulla E, Jouenne R, Combe B, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010;62:2458-66.
70. Chen D, Frezza M, Schmitt S, Kanwar J, Dou QP. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets. 2011;11:239-53.
71. Yokota S, Kishimoto T. Tocilizumab. Molecular intervention therapy in children with systemic juvenile idiopathic arthritis. Expert Rev Clin Immunol. 2010;6:735-43.
72. Ding C. Belimumab, an anti-BLyS human monoclonal antibody for potential treatment of inflammatory autoimmune diseases. Expert Opin Biol Ther. 2008;8:1805-14.
73. Goldenberg DM. Epratuzumab in the therapy of oncological and immunological diseases. Expert Rev Anticancer Ther. 2006;6:1341-53.